NIA Grant Expands DIAN Alzheimer's Study

A five-year, $43 million award will double enrollment in the long-running observational study of inherited Alzheimer's.

Updated on Nov. 19, 2026 in Alzheimer’s

Isometric editorial illustration of a row of amber-filled glass vials in a steel rack beside a closed brain-scanner housing under even light.
The National Institute on Aging awarded Washington University in St. Louis a five-year, $43 million grant to double enrollment in its DIAN study of inherited Alzheimer's. AI Illustration. Upload story photo >

Live Poll

Should the federal government spend more on Alzheimer's research?

The National Institute on Aging has awarded a five-year, $43 million grant to expand the DIAN Observational Study, and researchers will double the number of participants. The study, based at Washington University School of Medicine in St. Louis, has enrolled more than 750 people since 2008.

Why it matters

The study follows people who carry dominant Alzheimer's gene mutations and their relatives who do not, allowing researchers to track how the disease develops before symptoms appear. The expansion supports the work of the Knight Family DIAN Trials Unit, which aims to stop Alzheimer's before it begins.

The study has enrolled more than 750 people since 2008, and about three-quarters had no symptoms at enrollment. Each child of a parent with a dominant mutation has a 50% chance of inheriting it, and the study's long-term findings on how the disease develops remain to be determined.

The players

National Institute on Aging

The National Institute on Aging is a component of the National Institutes of Health that funds research on aging and age-related diseases, including Alzheimer's disease.

Washington University School of Medicine

Washington University School of Medicine in St. Louis is a leading academic medical center whose researchers direct the DIAN Observational Study.

Knight Family DIAN Trials Unit

The Knight Family DIAN Trials Unit is a research group that runs clinical trials aimed at preventing Alzheimer's disease in people with inherited gene mutations.

The details

The DIAN Observational Study gives the same memory tests, brain scans, and blood and spinal fluid analyses to participants and to relatives who did not inherit the mutation, allowing comparison between the two groups. The study involves institutions across the United States and sites in 10 other countries, and it now includes people treated with amyloid immunotherapy, some for more than 10 years.

Timeline

  1. 2008: The DIAN Observational Study launched at Washington University School of Medicine.

  2. 2010: Marty Reiswig began participating in the observational study.

  3. 2012: The Knight Family DIAN Trials Unit launched its first clinical prevention trial.

  4. Over the next five years: The $43 million National Institute on Aging award funds the study's expansion.

Health Landscape

The expansion builds on the DIAN Observational Study, which has tracked families with dominant Alzheimer's mutations since 2008 and has become a model for studying the disease before symptoms appear. It places the study alongside newer preventive trials that treat people up to 25 years before expected symptom onset, a shift from earlier efforts that began only after symptoms or plaque buildup were established.

For people with a parent who carried a dominant Alzheimer's mutation, the study offers a way to take part in research and learn about their own risk. Participants and relatives receive the same testing, which may guide decisions about joining future prevention trials.

The takeaway

Inherited Alzheimer's is not fixed in timing: because gene carriers can be studied before symptoms, researchers now have a window to test whether the disease can be stopped early. Anyone with a known family history should discuss research options with a physician or genetic counselor.

Further reading

For more background on the disease itself, see our Alzheimer's coverage.

Source note: This article includes information reported by News-Medical.

Live Poll

Should the federal government spend more on Alzheimer's research?